HB Wealth Management LLC Buys New Position in Insulet Co. (NASDAQ:PODD)

HB Wealth Management LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,351 shares of the medical instruments supplier’s stock, valued at approximately $273,000.

Several other institutional investors have also added to or reduced their stakes in the business. Sunbelt Securities Inc. purchased a new stake in shares of Insulet in the 1st quarter worth $29,000. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet during the fourth quarter valued at about $34,000. Jones Financial Companies Lllp purchased a new stake in Insulet in the fourth quarter worth about $40,000. CVA Family Office LLC raised its stake in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its stake in shares of Insulet by 159.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 156 shares during the period.

Wall Street Analyst Weigh In

PODD has been the subject of several analyst reports. Barclays increased their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Raymond James decreased their price objective on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. BTIG Research lowered their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. UBS Group increased their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Finally, OTR Global restated a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $225.29.

Insider Activity at Insulet

In other Insulet news, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the sale, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Insulet news, SVP Mark N. Field sold 2,131 shares of Insulet stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark N. Field sold 1,500 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now directly owns 12,875 shares in the company, valued at approximately $2,574,485. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,631 shares of company stock valued at $2,039,316. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

NASDAQ:PODD opened at $202.77 on Friday. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The company has a market cap of $14.20 billion, a price-to-earnings ratio of 61.45, a PEG ratio of 3.62 and a beta of 1.16. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $223.56. The stock’s 50 day simple moving average is $195.59 and its two-hundred day simple moving average is $183.62.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. During the same period in the previous year, the company earned $0.38 EPS. Insulet’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.